DexCom, Inc. (NASDAQ:DXCM) SVP Heather S. Ace sold 10,461 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $142.90, for a total value of $1,494,876.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

DexCom stock opened at $146.85 on Friday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 7.32 and a current ratio of 7.64. DexCom, Inc. has a 12 month low of $64.15 and a 12 month high of $156.16. The firm has a market cap of $12.94 billion, a PE ratio of 489.50 and a beta of 0.78.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 21st. The medical device company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.16 by $0.38. DexCom had a negative net margin of 12.32% and a positive return on equity of 4.98%. The business had revenue of $338.00 million for the quarter, compared to analysts’ expectations of $331.60 million. During the same period in the previous year, the company posted $0.10 EPS. DexCom’s revenue was up 52.9% on a year-over-year basis. As a group, equities analysts expect that DexCom, Inc. will post 0.46 earnings per share for the current fiscal year.

Several equities analysts have weighed in on the stock. Cowen lifted their price objective on shares of DexCom from $150.00 to $175.00 and gave the stock an “outperform” rating in a research report on Friday, February 22nd. Morgan Stanley lifted their price objective on shares of DexCom from $135.00 to $160.00 and gave the stock an “equal weight” rating in a research report on Monday, February 25th. BidaskClub cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Tuesday, November 20th. Canaccord Genuity lifted their price objective on shares of DexCom from $140.00 to $160.00 and gave the stock a “buy” rating in a research report on Friday, February 22nd. Finally, Piper Jaffray Companies lifted their price objective on shares of DexCom to $165.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 9th. Seven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $149.53.

Several institutional investors have recently bought and sold shares of the company. Prudential Financial Inc. boosted its holdings in DexCom by 2.2% in the fourth quarter. Prudential Financial Inc. now owns 4,668 shares of the medical device company’s stock worth $559,000 after purchasing an additional 100 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in DexCom by 1.6% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 8,293 shares of the medical device company’s stock worth $994,000 after purchasing an additional 131 shares in the last quarter. Equitable Trust Co. boosted its holdings in DexCom by 2.4% in the fourth quarter. Equitable Trust Co. now owns 6,500 shares of the medical device company’s stock worth $779,000 after purchasing an additional 150 shares in the last quarter. First Hawaiian Bank boosted its holdings in DexCom by 75.6% in the fourth quarter. First Hawaiian Bank now owns 395 shares of the medical device company’s stock worth $47,000 after purchasing an additional 170 shares in the last quarter. Finally, Marble Harbor Investment Counsel LLC boosted its holdings in DexCom by 0.5% in the fourth quarter. Marble Harbor Investment Counsel LLC now owns 34,840 shares of the medical device company’s stock worth $4,174,000 after purchasing an additional 180 shares in the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Heather S. Ace Sells 10,461 Shares of DexCom, Inc. (DXCM) Stock” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.thecerbatgem.com/2019/03/15/heather-s-ace-sells-10461-shares-of-dexcom-inc-dxcm-stock.html.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Read More: What is channel trading?

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.